Editas Medicine, Inc.
EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.47
Price-8.18%
-$0.22
1Y
Price
Market Cap
$222.103m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1380.1%
EBITDA Margin-1487.8%
Net Profit Margin-1403.3%
Free Cash Flow MarginRevenue
$38.901m
+20.4%
1y CAGR+86.0%
3y CAGR+58.8%
5y CAGREarnings
-$236.859m
+0.1%
1y CAGR-8.0%
3y CAGR-9.7%
5y CAGREPS
-$2.85
+1.0%
1y CAGR-1.5%
3y CAGR-4.3%
5y CAGRBook Value
$19.189m
$210.581m
Assets$191.392m
Liabilities$77.805m
DebtDebt to Assets
37.0%
-0.3x
Debt to EBITDAFree Cash Flow
-$204.936m
+6.5%
1y CAGR-9.7%
3y CAGR-8.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company